.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Acute Myeloid Leukemia (AML) management remains challenging, especially in patients with relapsed or refractory (R/R) disease. Recent breakthroughs suggest that the S100A9 inhibitor B2 could provide a new therapeutic strategy. Researchers identified S100A9 as a key driver of disease aggressiveness and suboptimal treatment outcomes. Consequently, targeting this protein may overcome traditional drug resistance mechanisms and improve patient fitness.
The study highlights how S100A9 regulates mitochondrial calcium levels in leukemic cells. B2 binds directly to S100A9 and reduces its overall abundance within the cell. This action triggers a rapid accumulation of mitochondrial calcium. This overload effectively disrupts essential survival pathways, specifically STAT5 and AKT activation. Furthermore, B2 shows high selectivity for S100A9-high AML cells. Importantly, it spares normal hematopoietic cells, which suggests a favorable safety profile for patients undergoing intensive therapy.
Experimental models demonstrated a significant reduction in leukemia burden after treatment with B2. Moreover, transcriptomic data confirmed that the drug effectively attenuates key oncogenic signals. These findings suggest that B2 represents a strong translational candidate for upcoming clinical trials. Thus, it offers a novel approach to targeting mitochondrial vulnerabilities in R/R AML while minimizing off-target effects.
S100A9 is a calcium-binding protein often overexpressed in AML. It is associated with high disease aggressiveness and a poor response to standard chemotherapy and targeted agents.
The S100A9 inhibitor B2 binds to S100A9 and reduces its intracellular abundance. This process induces a lethal accumulation of calcium in the mitochondria, which subsequently inhibits survival signaling and leads to cancer cell death.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Hu C et al. Targeting mitochondrial calcium homeostasis via novel S100A9 inhibitor B2 as a promising agent against AML. J Transl Med. 2026 May 14. doi: 10.1186/s12967-026-08256-1. PMID: 42135826.
Laouedj M et al. S100A9 induces differentiation of acute myeloid leukemia cells through TLR4. Blood. 2017;129(14):1980-1990.
Sheth AI et al. Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial Calcium. Cancer Discov. 2024;14(10):1922-1939.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new study identifies B2, a novel S100A9 inhibitor, as a promising treatment for R/R AML by inducing mitochondrial calcium overload in cancer cells....
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
